Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11133720.
- Also identified by PMC identifier 1723691.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To demonstrate that oral cyclosporin is successful in the management of steroid refractory post-keratoplasty atopic sclerokeratitis (PKAS). Series of three patients. The patients developed PKAS between 2 and 11 days after surgery. All cases failed to respond to oral prednisolone 60-80 mg daily for 10-30 days but resolved with the addition of systemic cyclosporin 5.0-7.5 mg/kg/day. There have been no relapses following withdrawal of therapy after 3-18 months. PKAS is an uncommon, but severe, complication of corneal graft surgery and often responds to oral prednisolone treatment. Oral cyclosporin results in rapid resolution of PKAS in steroid unresponsive cases.
Medical subject headings
- Cyclosporine
- Immunosuppressive Agents
- Keratitis
- Keratoplasty, Penetrating
- Scleritis